Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapleural Bevacizumab for MPE in NSCLC
NCT02054052Phase 2Completed
- Start
- Jan 2014
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in malignant pleural effusion (MPE), malignant pericardial effusion (MPE). Started Jan 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
malignant pleural effusion (MPE)malignant pericardial effusion (MPE)
Beyond the preview
Go deeper on NCT02054052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054052.